Rigel Pharmaceuticals (RIGL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

RIGL · Stock Price

USD 26.24+0.28 (+1.08%)

Market Cap: $486.9M

Historical price data

Market Cap: $486.9MPipeline: 38 drugs (6 Phase 3)Patents: 20Founded: 1996HQ: South San Francisco, United States

Sector Ranking#210 in Small Molecule Drugs #70 in Oncology (General)

Overview

Rigel Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a fully integrated commercial biotech with two marketed products: TAVALISSE® for chronic immune thrombocytopenia (ITP) and REZLIDHIA® for relapsed/refractory AML with an IDH1 mutation. The company's strategy centers on expanding the labels of its commercial assets, advancing its clinical pipeline in hematology-oncology and immunology, and pursuing strategic collaborations. With a seasoned leadership team and a focus on dysregulated signaling pathways, Rigel aims to build a sustainable portfolio in niche hematologic and oncologic markets.

HematologyOncologyImmunology

Technology Platform

Target-driven, mechanism-based discovery of small molecule inhibitors focused on dysregulated intracellular signaling pathways, with core expertise in kinase (SYK) and enzyme (IDH) inhibitor chemistry.

Pipeline

38

38 drugs in pipeline6 in Phase 3

Drug	Indication	Stage
Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3...	AML (Acute Myeloid Leukemia)	Approved
Fostamatinib Disodium + Placebo	Immune Thrombocytopenic Purpura	Phase 3
Fostamatinib disodium	Warm Antibody Autoimmune Hemolytic Anemia	Phase 3
Fostamatinib Disodium	Immune Thrombocytopenic Purpura	Phase 3
Fostamatinib + Placebo	Covid19	Phase 3

Funding History

2

Total raised:$92M

PIPE$50MUndisclosedDec 15, 2019

IPO$42MUndisclosedFeb 3, 2000

FDA Approved Drugs

3

REZLIDHIANDADec 1, 2022

GAVRETONDASep 4, 2020

TAVALISSENDAApr 17, 2018

Opportunities

Near-term growth is driven by expanding the commercial footprint and label of TAVALISSE in ITP and REZLIDHIA in AML.

The IRAK1/4 inhibitor program in LR-MDS represents a significant mid-term pipeline catalyst in a market with high unmet need.

Strategic collaborations, like the one with Eli Lilly on RIPK1, provide de-risked avenues for pipeline expansion into immunology.

Risk Factors

Key risks include commercial execution challenges in competitive markets, clinical trial failures for pipeline assets (notably the IRAK1/4 inhibitor), regulatory and safety setbacks for marketed products, and potential future financing needs that could dilute shareholders.

The company's valuation is also subject to high biotech sector volatility.

Competitive Landscape

In ITP, TAVALISSE competes with TPO-RAs and immunosuppressants, differentiating via its novel SYK inhibition mechanism. In mIDH1 AML, REZLIDHIA faces direct competition from other IDH inhibitors (ivosidenib, enasidenib). Rigel's strategy is to establish leadership in niche hematology indications rather than broad, crowded oncology markets.